SVF
Level C· Early Human ResearchProspective Study

[Exosomes from folic acid-treated subpatellar fat pad-derived mesenchymal stem cells promote M2 polarization of macrophages in vitro ].

Wang Z., Kong K., Jin M., Ng S., Fan W., Zhai Z.

Prospective Study on Knee Osteoarthritis, Osteoarthritis, published in Nan Fang Yi Ke Da Xue Xue Bao (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Nan Fang Yi Ke Da Xue Xue Bao (2026)
Country
China
Reported sample size
—
PMID
41540703
DOI
10.12122/j.issn.1673-4254.2026.01.18

Abstract (original English)

To evaluate the effect of exosomes derived from folic acid (FA)-treated infrapatellar fat pad mesenchymal stem cells (IPFP-MSCs) on M1 and M2 polarization of macrophages in vitro . Infrapatellar fat pad tissues were obtained from surgical patients without knee osteoarthritis to isolate IPFP-MSCs. The exosomes were extracted from the cell cultures with or without FA treatment and identified by transmission electron microscopy, TEM, NTA and Western blotting. RAW264.7 cells were induced with lipopolysaccharide (LPS) and incubated with exosomes from FA-treated or untreated IPFP-MSCs for 12 h, and Exos uptake was observed using confocal microscopy. The changes in expression levels of IL-1β, IL-6, TNF-α, iNOS, ARG1, MRC1, and CD206 in the macrophages were detected using qRT-PCR, ELISA, flow cytometry and immunofluorescence staining. The exosomes derived from IPFP-MSCs showed a typical cup shape, were positive for CD9 and CD81, and could be uptaken by macrophages. In LPS-induced macrophages, incubation with exosomes from FA-treated IPFP-MSCs significantly decreased the expressions of IL-1β, IL-6, TNF‑α, and NOS2, and increased the expressions of ARG1 and MRC1. Treatment of the macrophages with exosomes from FA-treated IPFP-MSCs significantly lowered CD86-positive cell percentage, increased CD206-positive cells and the CD206/CD86 ratio, lowered cellular expression of iNOS, and enhanced

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples, often without a control group.

How we grade evidence
ExosomesMesenchymal Stem CellsMacrophagesAnimalsMiceFolic AcidAdipose TissueHumansRAW 264.7 CellsTumor Necrosis Factor-alpha
KneeKnee OsteoarthritisOsteoarthritis
View on PubMedDOI

Related research